Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Registration Number
- NCT02264990
- Lead Sponsor
- AbbVie
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 595
- Subject must be ≥ 18 years of age with life expectancy > 12 weeks.
- Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.
- Subject must have NSCLC that is not amenable to surgical resection or radiation with curative intent at time of screening.
- Subject must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
- Subject has a known hypersensitivity to platinum compounds.
- Subject has peripheral neuropathy ≥ grade 2.
- Subject has squamous NSCLC, or an untreated known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic lymphoma kinase (ALK) gene rearrangement.
- Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Veliparib + Carboplatin + Paclitaxel Carboplatin Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles. After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Veliparib + Carboplatin + Paclitaxel Paclitaxel Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles. After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Investigator's Choice Chemotherapy Paclitaxel Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles: * Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m² * Cisplatin 75 mg/m² + pemetrexed 500 mg/m² * Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m² After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Veliparib + Carboplatin + Paclitaxel Pemetrexed Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles. After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Veliparib + Carboplatin + Paclitaxel Veliparib Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles. After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Investigator's Choice Chemotherapy Carboplatin Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles: * Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m² * Cisplatin 75 mg/m² + pemetrexed 500 mg/m² * Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m² After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Investigator's Choice Chemotherapy Pemetrexed Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles: * Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m² * Cisplatin 75 mg/m² + pemetrexed 500 mg/m² * Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m² After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred. Investigator's Choice Chemotherapy Cisplatin Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles: * Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m² * Cisplatin 75 mg/m² + pemetrexed 500 mg/m² * Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m² After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively. Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. Overall survival was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.
- Secondary Outcome Measures
Name Time Method Overall Survival in All Participants From randomization up to the data cut-off date of 15 July 2019; the median OS follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively. Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. OS was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.
Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively. Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death (all causes of mortality), whichever occurred first.
PD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
PFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cutoff date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring \> 26 weeks and \> 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 5.2 and 6.3 months in each group, respectively. Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.
CR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.Objective Response Rate (ORR) in All Participants Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 6.7 and 5.9 months in each group, respectively. Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per RECIST version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.
CR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.Progression Free Survival (PFS) in All Participants From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively. Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per RECIST version 1.1 or death (all causes of mortality), whichever occurred first.
PD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
PFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cut-off date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring \> 26 weeks and \> 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.
Trial Locations
- Locations (140)
Multiscan s.r.o. /ID# 132689
🇨🇿Pardubice, Czechia
Klinik Loewenstein GmbH /ID# 131925
🇩🇪Löwenstein, Germany
Inonu University /ID# 136569
🇹🇷Malatya, Turkey
St. Antonius Ziekenhuis /ID# 133635
🇳🇱Nieuwegein, Netherlands
James Paget University Hosp /ID# 131954
🇬🇧Great Yarmouth, United Kingdom
Castle Hill Hospital /ID# 135489
🇬🇧Cottingham, United Kingdom
Colchester General Hospital /ID# 133929
🇬🇧Colchester, United Kingdom
Royal Gwent Hospital /ID# 133935
🇬🇧Gwent, United Kingdom
Charing Cross Hospital /ID# 131959
🇬🇧London, United Kingdom
Huddersfield Royal Infirmary /ID# 132854
🇬🇧Huddersfield, United Kingdom
York Hospital /ID# 132859
🇬🇧York, United Kingdom
LA Hem-Oncology Med Group /ID# 131639
🇺🇸Los Angeles, California, United States
Herbert Herman Cancer Center /ID# 130239
🇺🇸Lansing, Michigan, United States
Allegheny General Hospital /ID# 134049
🇺🇸Pittsburgh, Pennsylvania, United States
Clearview Cancer Institute /ID# 131434
🇺🇸Huntsville, Alabama, United States
California Cancer Assoc. R&E /ID# 131392
🇺🇸Encinitas, California, United States
University of South Alabama /ID# 131518
🇺🇸Mobile, Alabama, United States
CBCC Global Research, Inc. at /ID# 132709
🇺🇸Bakersfield, California, United States
California Cancer Assoc. R&E /ID# 131949
🇺🇸Encinitas, California, United States
St Jude Hospital dba St Joseph /ID# 132943
🇺🇸Santa Rosa, California, United States
Icri /Id# 132942
🇺🇸Whittier, California, United States
NorthShore University HealthSystem - Evanston Hospital /ID# 130200
🇺🇸Evanston, Illinois, United States
Goshen Center for Cancer Care /ID# 130216
🇺🇸Goshen, Indiana, United States
Washington University-School of Medicine /ID# 131651
🇺🇸Saint Louis, Missouri, United States
Gabrail Cancer Center Research /ID# 130205
🇺🇸Canton, Ohio, United States
Albert Einstein Medical Center /ID# 134498
🇺🇸Philadelphia, Pennsylvania, United States
UT Southwestern Medical Center /ID# 130236
🇺🇸Dallas, Texas, United States
Hospital Britanico /ID# 134874
🇦🇷Rosario, Santa FE, Argentina
St George Hospital /ID# 132481
🇦🇺Kogarah, New South Wales, Australia
Southern Medical Day Care Ctr /ID# 132482
🇦🇺Wollongong, New South Wales, Australia
Victoria Hospital /ID# 132161
🇨🇦London, Ontario, Canada
Windsor Regional Hospital /ID# 135989
🇨🇦Windsor, Ontario, Canada
Krajska nemocnice Liberec a.s. /ID# 132694
🇨🇿Liberec, Czechia
Flinders Centre for Innovation /ID# 134288
🇦🇺Bedford Park, South Australia, Australia
Royal Hobart Hospital /ID# 132477
🇦🇺Hobart, Tasmania, Australia
Univ Hosp Ostrava-Poruba /ID# 132690
🇨🇿Ostrava, Czechia
Vseobecna Fakultni Nemocnice /ID# 135118
🇨🇿Prague, Czechia
Lungen Clinic Grosshansdorf /ID# 131928
🇩🇪Grosshansdorf, Germany
Charite-Univ. Berlin, Benjamin-Franklin /ID# 131927
🇩🇪Berlin, Germany
Univ Klinik Eppendorf Hamburg /ID# 131926
🇩🇪Hamburg, Germany
Vaasa Central Hospital /ID# 131930
🇫🇮Vaasa, Finland
Petz Aladar Megyei Oktato Korh /ID# 132741
🇭🇺Gyor, Hungary
Sendai Kousei Hospital /ID# 135491
🇯🇵Sendai-shi, Miyagi, Japan
Kishiwada City Hospital /ID# 136548
🇯🇵Kishiwada, Japan
Dong-A University Hospital /ID# 131609
🇰🇷Busan, Busan Gwang Yeogsi, Korea, Republic of
Inha University Hospital /ID# 147924
🇰🇷Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of
Seoul National Univ Bundang ho /ID# 131610
🇰🇷Seongnam, Gyeonggido, Korea, Republic of
Chonnam National University Hospital /ID# 131612
🇰🇷Gwangju, Jeonranamdo, Korea, Republic of
Samsung Medical Center /ID# 132471
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Chungbuk National Univ Hosp /ID# 131611
🇰🇷Cheongju, Korea, Republic of
Vrije Universiteit Medisch Centrum /ID# 131967
🇳🇱Amsterdam, Netherlands
Ziekenhuis St. Jansdal /ID# 131965
🇳🇱Harderwijk, Netherlands
Jeroen Bosch Ziekenhuis /ID# 131968
🇳🇱S Hertogenbosch, Netherlands
Canterbury District Health Boa /ID# 132469
🇳🇿Christchurch, New Zealand
Wellington Hospital (Capital and Coast District Health Board) /ID# 132470
🇳🇿Wellington, New Zealand
archangel Clinical Oncology /ID# 132376
🇷🇺Arkhangelsk, Russian Federation
Belgorod Oncology Dispensary /ID# 142638
🇷🇺Belgorod, Russian Federation
Moscow Regional Onc Dispensary /ID# 132381
🇷🇺Balashikha, Russian Federation
Dr Albert, Bouwer and Jordaan Incorporated /ID# 131775
🇿🇦Pretoria, Gauteng, South Africa
The Oncology Centre /ID# 131773
🇿🇦Durban, Kwazulu-Natal, South Africa
Mary Potter Oncology Centre /ID# 131776
🇿🇦Pretoria, Gauteng, South Africa
Sandton Oncology Medical Group /ID# 131774
🇿🇦Johannesburg, South Africa
Hospital Universitario Fundacion Alcorcon /ID# 132909
🇪🇸Alcorcon, Spain
Hospital General Universitario Alicante /ID# 132881
🇪🇸Alicante, Spain
Hospital Universitario Dexeus - Grupo Quironsalud /ID# 132876
🇪🇸Barcelona, Spain
Hospital Universitario Vall d'Hebron /ID# 132871
🇪🇸Barcelona, Spain
Hospital Universitario La Paz /ID# 132870
🇪🇸Madrid, Spain
MD Anderson Madrid /ID# 132905
🇪🇸Madrid, Spain
Hospital Universitario HM Sanchinarro /ID# 132869
🇪🇸Madrid, Spain
Hospital Clinico Universitario de Valencia /ID# 132873
🇪🇸Valencia, Spain
China Medical University Hosp /ID# 131870
🇨🇳Taichung City, Taichung, Taiwan
Taipei Veterans General Hosp /ID# 131871
🇨🇳Taipei City, Taiwan
Hacettepe University Medical Faculty /ID# 131913
🇹🇷Ankara, Turkey
Uludag University Medical Faculty /ID# 131915
🇹🇷Bursa, Turkey
Dicle Universitesi Tip /ID# 136570
🇹🇷Diyarbakir, Turkey
Ankara Univ Medical Faculty /ID# 131914
🇹🇷Ankara, Turkey
Gaziantep Universitesi Med /ID# 131917
🇹🇷Gaziantep, Turkey
Norfolk and Norwich Univ Hosp /ID# 131953
🇬🇧Norwich, Norfolk, United Kingdom
Royal United Hospitals Bath /ID# 132851
🇬🇧Bath, United Kingdom
Belfast City Hospital /ID# 132858
🇬🇧Belfast, United Kingdom
Heart of England NHS Foundation Trust /ID# 132855
🇬🇧Birmingham, United Kingdom
Scunthorpe General Hospital /ID# 133931
🇬🇧Doncaster, United Kingdom
Odense Universitets Hospital /ID# 131912
🇩🇰Odense C, Syddanmark, Denmark
Dr. Suat Seren Gogus Has /ID# 136568
🇹🇷Izmir, Turkey
Coiba /Id# 132153
🇦🇷Berazategui, Buenos Aires, Argentina
Centro Investigacion Pergamino /ID# 132152
🇦🇷Pergamino, Argentina
Cancer Center of Acadiana /ID# 133611
🇺🇸Lafayette, Louisiana, United States
MD Anderson Cancer Center at Cooper - Camden /ID# 131490
🇺🇸Camden, New Jersey, United States
Veszprem Megyei Tudogyogyintez /ID# 132739
🇭🇺Farkasgyepu, Hungary
Aichi Cancer Center Hospital /ID# 134129
🇯🇵Nagoya-shi, Aichi, Japan
Kurume University Hospital /ID# 134117
🇯🇵Kurume-shi, Fukuoka, Japan
Hokkaido University Hospital /ID# 134123
🇯🇵Sapporo-shi, Hokkaido, Japan
Kindai University Hospital /ID# 134112
🇯🇵Osaka-sayama-shi, Osaka, Japan
Sverdlovsk Regional Oncology Center Dispensary /ID# 132375
🇷🇺Ekaterinburg, Sverdlovskaya Oblast, Russian Federation
Orenburg Regional Clinical Onc /ID# 132371
🇷🇺Orenburg, Russian Federation
Highlands Oncology Group /ID# 131250
🇺🇸Springdale, Arkansas, United States
Matrahaza Gyogyintezet /ID# 132743
🇭🇺Kékesteto, Hungary
Shaare Zedek Medical Center /ID# 132834
🇮🇱Jerusalem, Israel
Strategic medical systems LLC /ID# 206383
🇷🇺Sankt-Peterburg, Russian Federation
The Jones Clinic, PC /ID# 130215
🇺🇸Germantown, Tennessee, United States
CSSS Alphonse-Desjardins, CHAU de Levis /ID# 132155
🇨🇦Quebec City, Quebec, Canada
Satakunnan Sairaanhoitopiiri /ID# 133632
🇫🇮Pori, Finland
Orszagos Koranyi Pulmonologiai Intezet /ID# 132738
🇭🇺Budapest XII, Budapest, Hungary
Assaf Harofeh Medical Center /ID# 132830
🇮🇱Be'er Ya'akov, Israel
Meir Medical Center /ID# 132832
🇮🇱Kfar Saba, Israel
The Cancer Institute Hospital Of JFCR /ID# 135492
🇯🇵Koto-ku, Tokyo, Japan
Hiroshima Citizens Hospital /ID# 135130
🇯🇵Hiroshima, Japan
State Regional Budgetary Healthcare Institution " Murmansk Regional Oncology Dis /ID# 137087
🇷🇺Murmansk, Russian Federation
Ogarev Mordovia State Univ /ID# 132377
🇷🇺Saransk, Russian Federation
GVI Oncology /ID# 133268
🇿🇦Port Elizabeth, Eastern Cape, South Africa
Instituto de Oncologia de Rosa /ID# 132150
🇦🇷Rosario, Santa FE, Argentina
Debreceni Egyetem Klinikai Kozpont /ID# 132742
🇭🇺Debrecen, Hungary
Sheba Medical Center /ID# 132833
🇮🇱Ramat Gan, Israel
Kanagawa Cardiovascular and Respiratory Center /ID# 134127
🇯🇵Yokohama-shi, Kanagawa, Japan
N.N. Petrov Research Inst Onc /ID# 137084
🇷🇺St. Petersburg, Russian Federation
Moscow Res Onc Inst Hertsen /ID# 132370
🇷🇺Moscow, Russian Federation
Qe Ii Hsc /Id# 133408
🇨🇦Halifax, Nova Scotia, Canada
CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 133441
🇭🇺Miskolc, Borsod-Abauj-Zemplen, Hungary
Koch Robert Hospital /ID# 133440
🇭🇺Edelény, Hungary
Osaka City General Hospital /ID# 134115
🇯🇵Osaka-shi, Osaka, Japan
National Cancer Center Hospital /ID# 135129
🇯🇵Chuo-ku, Tokyo, Japan
Yamaguchi - Ube Medical Center /ID# 135284
🇯🇵Ube-shi, Yamaguchi, Japan
Catharina Ziekenhuis /ID# 131966
🇳🇱Eindhoven, Netherlands
Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Resea /ID# 137085
🇷🇺Moscow, Moskva, Russian Federation
Netcare Oncology Intervent Ctr /ID# 131777
🇿🇦Cape Town, Western Cape, South Africa
LLC BioEq Ltd. /ID# 132372
🇷🇺St. Petersburg, Russian Federation
Cape Town Oncology Trials /ID# 132734
🇿🇦Cape Town, Western Cape, South Africa
Hospital Duran i Reynals /ID# 132879
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
GVI Rondebosch Oncology Centre /ID# 132732
🇿🇦Cape Town, Western Cape, South Africa
Dalin Tzu Chi General Hospital /ID# 131872
🇨🇳Dalin Township, Taiwan
Taipei Medical University Hospital /ID# 133817
🇨🇳Taipei City, Taiwan
Leicester Royal Infirmary /ID# 133930
🇬🇧Leicester, England, United Kingdom
Cheltenham General Hospital /ID# 131951
🇬🇧Cheltenham, Gloucestershire, United Kingdom
Royal Blackburn Hospital /ID# 132853
🇬🇧Blackburn, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Freeman Hospital /ID# 131661
🇬🇧Newcastle Upon Tyne, United Kingdom
University of Louisville /ID# 130217
🇺🇸Louisville, Kentucky, United States
Henry Ford Health System /ID# 130234
🇺🇸Detroit, Michigan, United States
Univ Oklahoma HSC /ID# 132888
🇺🇸Oklahoma City, Oklahoma, United States
Univ Texas HSC San Antonio /ID# 132972
🇺🇸San Antonio, Texas, United States
University of Florida - Archer /ID# 132408
🇺🇸Gainesville, Florida, United States